Tumor antigens is at the core of cancer immunotherapy, however, the ideal antigen selection is difficult especially in poorly immunogenic tumors. In this study, we designed a strategy to modify hepatocellular carcinoma (HCC) cells by surface expressing anti-CD3scfv within the tumor site strictly, which depended on the E1A-engineered human umbilical cord mesenchymal stem cells (HUMSC.E1A) delivery system. Subsequently, membrane-bound anti-CD3scfv actived the lymphocytes which lysed HCC cells bypassing the expression of antigens or MHC restriction. First, we constructed the anti-CD3scfv gene driven by human a-fetoprotein (AFP) promoter into an adenoviral vector and the E1A gene into the lentiviral vector. Our results showed that anti-CD3scfv could specifically express on the surface of HCC cells and activate the lymphocytes to kill target cells effectively in vitro. HUMSC infected by AdCD3scfv followed by LentiR.E1A could support the adenoviral replication and packaging in vitro 36 h after LentiR.E1A infection. Using a subcutaneous HepG2 xenograft model, we confirmed that AdCD3scfv and LentiR.E1A co-transfected HUMSC could migrate selectively to the tumor site and produce considerable adenoviruses. The new generated AdCD3scfv infected and modified tumor cells successfully. Mice injected with the MSC.E1A.AdCD3scfv and lymphocytes significantly inhibited the tumor growth compared with control groups. Furthermore, 5-fluorouracil (5-FU) could sensitize adenovirus infection at low MOI resulting in improved lymphocytes cytotoxicity in vitro and in vivo. In summary, this study provides a promising strategy for solid tumor immunotherapy.
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, with a global incidence of over 700,000 new cases per year. 1 A range of therapies are used in the management of HCC according to the tumor burden and the severity of underlying liver disease. However, the overall prognosis is dismal, with a 5-year survival rate of approximately 5-6% because of the low effectiveness of available treatments. [2] [3] [4] Immunotherapeutic interventions have changed the landscape of cancer therapy due to the encouraging clinical results. Already several immunotherapies, such as tumor vaccines, adoptive cell therapy or immune checkpoint inhibitors, have demonstrated safety and feasibility in HCC patients. Unfortunately, most of them failed to demonstrate clinical efficacy. 5, 6 Multiple mechanisms contribute to the weak and often inefficient T cell responses in HCC patients. Tumor antigens is at the core of cancer immunotherapy, however, HCCspecific tumor associated antigens (TAAs) are limited in number. So far, several HCC-specific TAAs that are targeted by T cells have been identified: (a) overexpressed antigens (TERT); (b) oncofetal antigens (AFP, GPC3); and (c) cancer/ testis antigens (MAGE-A, SSX-2, NY-ESO-1). 7, 8 However, most of the clinical trials based on such TAAs only showed limited improvements. [9] [10] [11] Therefore, new and more specific
TAAs and/or epitopes should be identified. Furthermore, functional studies have indicated that HCCs lack the antigenprocessing machinery necessary to effectively present tumor antigens, allowing escape from cytotoxic CD8 T-lymphocyte killing. [12] [13] [14] On the other hand, as HCC is an extraordinarily heterogeneous disease, not all cancer cells within the tumor express the same antigens. 15 It has been indicated immune system exerts a selective pressure on transformed cells that display weak antigens or no antigen at all. Those tumor variants will escape the immune elimination and eventually lead to tumor-sculpting (a phenomenon known as "immunoediting"). Such new formed tumor is extremely lack of antigenicity, which poses severe challenge for cancer immunotherapy. [16] [17] [18] [19] Therefore, it is important to explore effective approaches to overcome these antigen limitations.
It has been reported that CTLs mediated cytolysis has two basic requirements: (a) an activated state of the effector cell, and (b) intimate contact between effector and target cells. These requirements can also be met through separate pathways except MHC-antigen mechanism. This form of cytolysis has been designated "sideways killing." 20 Evidence in vitro
showed that CTLs could lyse Fc receptor-bearing target cells effectively in the presence of anti-CD3 monoclonal antibodies through the bridge of Fc fragment. 21 Furthermore, Steven J.Mentzer demonstrated that a variety of mouse tumor cell lines could be killed by CTLs when the anti-CD3 monoclonal antibody was inserted directly into the tumor cell membrane. 22 Stable expression of anti-CD3 single-chain antibody on tumor cells could also mobilize polyconal lymphocytes in a non-MHC restricted fashion. 23, 24 These results indicate that genetically modification of tumor cells with anti-CD3 antibody provide a novel therapeutic strategy for tumors independent of the expression of antigens or MHC restriction. Nevertheless, transgene delivery remains a challenge in vivo, which significantly limits the method application.
MSCs have the ability to migrate toward malignant tumors and track microscopic metastasis. Genetically engineered MSCs retain this property and have been indicated as the most attractive vehicle for tumor targeted therapy. [25] [26] [27] [28] [29] Our previous research confirmed that E1A gene engineered human umbilical cord mesenchymal stem cells (HUMS-C.E1A) could serve as carriers and amplifiers in adenovirus delivery to tumor site, which targeted the therapy gene and finally suppressed hepatocarcinoma specifically. 30 In this study, we explored to modify the tumor cell surface by antiCD3scfv locoregionally based on the HUMSC.E1A delivery system. Schematic representation of the therapeutic strategy is shown in Supporting Information, Figure S1 . First, we constructed an adenoviral vector contained the membranebound anti-CD3scfv gene sequence. When HUMSC.E1A was infected by this adenovirus, it would not only delivered adenoviral vector to tumor sites, but support the adenoviral replication and packaging. The new generated adenovirus infected hepatoma cells to express anti-CD3scfv proteins which were anchored on the cell surface. Membrane-bound anti-CD3scfv actived polyclonal lymphocytes and triggered lymphocytes mediated cytolysis strictly within tumor sites.
To further enhance anti-tumor specificity, the expression of anti-CD3scfv is driven by the human a-fetoprotein (AFP) promoter cloned by our previous study. Finally, we evaluated the synergistic antitumor effect of this targeted therapeutic system in combination with 5-fluorouracil (5-FU) in the subcutaneous hepatic xenograft tumor model.
What's new?
Cancer immunotherapy through antigen selection is difficult to apply in poorly immunogenic tumors. Genetic modification of tumor cells with anti-CD3 antibody has been proposed as an alternative therapeutic strategy. Transgene delivery, however, remains a challenge in vivo. Here, the authors genetically modified hepatocellular carcinoma (HCC) cells with a constructed membrane-bound anti-CD3scfv gene within the tumor site using the E1A-engineered human umbilical cord mesenchymal stem cells (HUMSC.E1A) transgene system. They found that membrane-bound anti-CD3scfv activated lymphocytes, which lysed HCC cells bypassing the expression of antigens or MHC restriction. The findings highlight the approach as a promising strategy for solid tumor immunotherapy. 
Materials and Methods

Cell lines
Membrane-bound anti-CD3scfv detection on transduced cells
Western blot, flow cytometry and immunofluorescence analysis were performed to confirm the expression and cell surface binding of anti-CD3scfv protein. HepG2, Huh7, HL-7702 and MCF-7 cell lines were infected with AdCD3scfv or AdTrack at 100 MOI for 48 hr, respectively.
In western blot analysis, target proteins were detected by primary antibodies against HA tag (Abcam, ab18181) or GAPDH (Cell Signaling Technology, D16H11) followed by corresponding secondary antibodies conjugated with horseradish peroxidase (HRP). Then, blots were visualized using the ECL (Millipore) with Image Quant LAS-4010 (GE Healthcare). The AdTrack transduced cells were used as empty control.
In flow cytometry, transduced cells were stained with mouse anti-HA tag antibody (Abcam, ab18181) for 30 min at room temperature and washed twice. The secondary antibody APCconjugated goat anti-mouse IgG H&L (Abcam, ab130782) was added, then incubated for another 30 min and washed once. Then the cells were analyzed by flow cytometry (BD, FACS LSRII) and results were analyzed with FlowJo software.
In immunofluorescence analysis, transfected cells were fixed with 4% paraformaldehyde, and blocked with 1% BSA for 1 hr at 228C. Samples were incubated with mouse anti-HA tag primary antibody (1/1000 in diluent) for 1 hr at 228C. APC-conjugated goat anti-mouse IgG (1/1000 in diluent) was used as the secondary antibody and incubated for another1 hr. Nuclei were stained with DAPI (Sigma, D9564) for 5 min. Images were captured using a two-photon laser scanning confocal microscope (OLYMPUS, FV1200 MPE).
Lymphocytes binding assay
HepG2 cells were infected with AdCD3scfv or AdTrack at 100 MOI for 48 hr and were seeded in 24-well plates (8 3 10 4 /well) overnight. PBMCs were added to each well at E:T of 10:1 for 3 hr at room temperature with or without 25 mg soluble anti-CD3 mAb (eBioscience, 4283330). Non-adherent cells were removed by gently washing the wells five times with medium. Adherent lymphocytes were observed under a light microscope (4003). For the study of combinatory antitumor effects of AdCD3scfv and 5-FU, HepG2 cells were pretreated with 5-FU (0.5 lg/mL) or not for 24 hr, and infected by AdCD3scfv at 10, 25, 50 MOI respectively for 48 hr. Next, the cells were seeded in 96-well plates (1 3 10 4 /well), then PBMC were added at the E:T of 10:1 and cocultured for 12 hr. Cytotoxicity detection was performed as described above.
Cytotoxicity assays in vitro
Cytokine release assays
Various target cells mentioned in 2.4 were incubated with PBMC at the E: T of 10:1 for 24 hr. The supernatants were harvested to measure the cytokines including IL-2, IFN-g and TNF-a using ELISA kits (R&D, D2050, VAL104, VAL105) according to the manufacturer's instructions. The supernatants from PBMC cultured alone were also harvested and used as control groups to exclude the natural cytokine release. Absorbance was measured with Hybrid Microplate Reader (Biotek, Synergy H4) at 570 nm.
Dynamic imaging by living cells workstation
To monitor the dynamic interaction of cells in the coculture system, AdCD3scfv or AdTrack infected HePG2 cells (green) were seeded into 24-well plates (5 3 10 4 /well) overnight, then mixed with PBMC at 1:10 and centrifuged 2503g for 2 min .Then cocultured cells were imaged using living cells workstation (Nikon, Nikon Ti-e) for 15 hr. The exposure time was 3 sec and pictures were captured every 10 min. Imaging data were analyzed using Elements 3.1 and Velocity 6.1 software.
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Generation of various antitumour effector cells
PBMCs were stained with fluorochrome-conjugated monoclonal antibodies against the following human surface antigens: CD3-FITC, CD4-APC, CD8-APC, CD56-APC (Biolegend, 317306, 357407, 300912, 318309). Then, CD3
1 T, CD3
1 NK cells were sorted respectively by flow cytometry (BD, FACS AriaIII) and cultured with IL-2 (100 U/mL; R&D, 202-IL-010).
Production of adenovirus in E1A modified MSC in vitro
First, we quantified the concentration of pAdTrack plasmid and diluted gradiently. Digital PCR was performed by QX200 Droplet Digital PCR system to examine the conserved region of hexon gene (nucleotides 21049-21334 of Ad5), which could direct reflect the adenoviral DNA copy number. The primers were designed as follows: 5 0 -GGTGGCCATTACC TTTGACTCTTC-3 0 and 5 0 -CCACCTGTTGGTAGTCCTTGT ATTT AGTATCATC-3 0 .Then, standard curve for adenovirus quantification was generated based on the number of plasmid DNA and concentrations.
Next, the HUMSC were infected with AdTrack at 500 MOI for 8 hr, washed twice with PBS and incubated overnight. Then, cells were transduced with lentiviruses (LentiR or LentiR.E1A) with 8 lg/mL polybrene (Sigma, 107689) for 6 hr, washed twice with PBS and cultured in the incubator. The time that lentiviruses began to infect was set as 0 hr. HUMSC and its supernatant were harvested at indicated time points, from which the adenoviral DNA was extracted using the High Pure Viral Nucleic Acid Extraction Kit (Roche, 11858874001) and concentrations were detected by NanoDrop 2000. Finally, DNA copy numbers were calculated according to the standard curve.
Transwell migration assay
The migratory ability of virus-loaded HUMSC was determined using cell culture inserts (BD Falcon) with 8 lm pore filters. HepG2 cells (5 3 10 4 /well) were seeded in the lower chamber overnight. Then, the adenovirus and lentivirus coinfected HUMSC as described above were plated in the top chamber (1 3 10 5 /well) within serum-free medium at 12 hr after lentivirus infection. Co-culture system was incubated for 20 hr. Filters were stained with 0.1% crystal violet for 20 min and washed twice with PBS. The number of cells that had migrated to the lower side was counted under a light microscope with five high-power fields randomly (2003) . Experiments were done in triplicate.
Immunofluorescence analysis for the expression of antiCD3scfv in vivo
Female BALB/c athymic nude mice 5-6 weeks were injected subcutaneously with 2 3 10 6 HepG2 cells into right armpits. Seven days later when solid tumors reached 50-100 mm 3 in size, mice were randomized into 3 groups according to the situations of HUMSC infected by viruses: (1) MSC.LentiR.AdCD3scfv; (2) MSC.E1A.AdTrack; (3) MSC.E1A.AdCD3 scfv. These MSCs were co-infected as described in 2.9 and injected intravenously with 1 3 10 6 cells into each mouse. The subcutaneous hepatocarcinoma model mice were sacrificed at day1, 4 and Day 6 after treatment. Immunofluorescence was performed on the tumor tissues. Samples were stained with mouse anti-HA tag primary antibody (Abcam, ab18181) and APC-conjugated secondary antibody (Abcam, ab130782) to detect anti-CD3scfv target protein. Meanwhile, samples were incubated with a rabbit anti-GFP (FITC -conjugated) antibody (Abcam, ab66180) to indicate the adenovirus infection. Nuclei were stained with DAPI (Sigma, D9564). Images were captured by a two-photon laser scanning confocal microscope (OLYMPUS, FV1200 MPE).
Anti-tumor effect on subcutaneous hepatocarcinoma tumor model
Female BALB/c nude mice 5-6 weeks old were inoculated subcutaneously with 2 3 10 6 HepG2 cells into right armpits.
When solid tumors reached 50-100 mm 3 in size, mice were randomized into 8 groups (6 mice for each group) as following: (1) PBS; (2) MSCs were co-infected by methods as described in 2.9. Various treated MSCs were injected into each mouse (iv, 1 3 10 6 cells) at days 7 of tumor inoculation, followed by PBMC infusion (iv, 6 3 10 6 cells) at days 10. Besides, 5-FU was given (ip, 20 mg/kg) every other day after MSCs injection for three times. At days 21, the same treatment was given one more time. Growing tumors were measured using a vernier caliper in two perpendicular dimensions every three days, and the tumor volumes were calculated using the following formula:
/2, where L represents the longest axis of the tumors and W represents the axis perpendicular to L. Mice were sacrificed when the tumors reached 2,000 mm 3 in size, and tumor were dissected from each mouse and weighed.
Statistical analysis
The data were analyzed using independent sample t tests and represented as mean 6 SD. p < 0.05 was considered to be statistically significant and p < 0.01 were considered to be highly statistically significant.
Results
Specific expression of anti-CD3scfv on hepatoma cell surface
We successfully constructed two adenoviral vectors using the anti-human CD3scfv sequence identified in our laboratory. The one named AdCD3scfv was composed of the AFP promoter fragment, signal peptide, anti-CD3scfv gene, transmembrane domain and the GFP sequence and was used for the following function study. The other one named AdTrack contained only the GFP sequence and was used as a control vector ( Supporting Information, Fig. S2 ). We used AdCD3scfv or AdTrack to infect four cell lines at 100MOI respectively: HepG2 and Huh7 were AFP 1 cell lines, but HL-7702 and MCF-7 were AFP -. Western blot was performed to test anti-CD3scfv protein expression. As shown in Figure 1a , when infected by AdCD3scfv, the fusion protein was detected only in HepG2 and Huh7; by contrast, no protein bands was observed in both HL-7702 and MCF-7. When infected by AdTrack, there is no protein expression in all four cell lines. The ability of anti-CD3scfv proteins to be expressed on the surface of cells was examined by immunofluorescence analysis. As shown in Figure 1b, (Fig. 1c) . All of the above results confirmed that the anti-CD3scfv proteins driven by AFP promoter had a specific expression in hepatoma cells and were successfully attached to the cell surface.
Furthermore, we observed the binding of lymphocytes to AdCD3scfv transfected HepG2 cells, but the addition of soluble anti-CD3 mAb completely blocked the binding (Fig.   1   d) . Moreover, typical cell interaction including binding and then lysis were examined by confocal microscopic video imaging at indicated time points (Fig. 1e) . These results showed that the surface anti-CD3scfv proteins were effective.
Specific cytotoxicity against hepatoma cells
In vitro assay of the specific cytotoxicity against hepatoma cells, HepG2, Huh7, HL-7702 and MCF-7 infected by AdCD3scfv or AdTrack at 100MOI and the corresponding uninfected cells were used as target cells and cocultured with PBMCs at different E: T ratios. CytoTox96V R Non-Radioactive Cytotoxicity Assay indicated that PBMCs could initiate specific lysis on the two AFP 1 HCC cell lines when infected by
AdCD3scfv at an E:T ratio of 2.5:1; when E:T ratio was 10:1, the cytotoxicity could be 78.59 6 7.50% and 63.26 6 6.21%, respectively, and increased as the E:T ratio increase; however, for the uninfected or infected by AdTrack cells, PBMCs showed almost no killing function; moreover, nearly no cytotoxic death was detected in HL-7702 and MCF-7cells at any conditions (Fig. 2a) (Fig. 2b) . Since the T cells activation and cytotoxicity was also associated with cytokines secretion, the classic cytokines of IL-2, IFN-g and TNF-a was detected to evaluate the activation efficacy of PBMCs incubated with target cells. In the supernatant of HepG2.anti-CD3scfv 1 PBMCs or Huh7.anti-CD3scfv 1 PBMCs coculture system, the concentrations of IL-2 was 980. 26 Fig. 2c-e) . Moreover, we conducted sequential microscope imaging of HepG2 cells (GFP
1
) cocultured with PBMCs. We found that anti-CD3scfv modified HepG2 cells underwent rapid elimination within 15 hr when exposed to PBMCs (Supporting Information, Video S1), whereas empty AdTrack transduced HepG2 cells scarcely experienced cytotoxic lysis (Supporting Information, Video S2).
To study the membrane-bound antiCD3scfv engaged cells in more detail, the cytotoxic activity of various kinds of effector cells in PBMCs was investigated. No matter PBMCs or purified CD3
CD4
1 , CD3
1
CD8
1 and all CD3 1 T cells could exhibit robust cytotoxicity against HepG2 cells transfected by AdCD3scfv ( Supporting Information, Fig. S3A ). In contrast to the above situation, pure CD3 -CD56 1 NK cells showed 33.7% killing of control HepG2.AdTrack cells. However, anti-CD3scfv expression did not increase the cytotoxic activity of NK cells. Since the proportion of NK cell population in PBMCs is about 5%-10%, when we use PBMCs as effector cells at E:T of 10:1, the relative ratio of NK cells to target cells is only 0.5:1-1: 1. Therefore, we reset the E:T ratio to 1:1, the levels of NK cell-induced killing significantly reduced approximately to 5% in both HePG2.AdTrack and HePG2.AdCD3scfv group ( Supporting Information, Fig. S3B ).
In conclusion, both CD8 1 and CD4 1 T cells exhibited efficient lysis of target cells mediated by the membrane-bound anti-CD3scfv. Moreover, the tumor cell lysis detected was mainly due to the contribution of T cell subsets when used PBMCs as effector cells.
5-FU sensitizes AdCD3scfv infection at low MOI resulting in improved lymphocytes cytotoxicity
Mobilization of cytotoxic T cells was determined by the antiCD3scfv expression levels on the tumor cell surface. Now we speculated that improving AdCD3scfv uptake especially at the lower MOI would increase the expression intensity of membrane-bound anti-CD3scfv, which finally led to more T cell activation. It has been demonstrated in our previous study that expression of adenoviral attachment receptor (CAR) and the major internalization receptors amb3 integrins could be increased in the presence of 5-FU causing a higher
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Zhang et al. viral uptake. 30 Therefore, we pre-treated the HepG2 cells with low dose of 5-FU (0.5 lg/mL or 1 lg/mL) before adenovirus infection at different MOI. As shown in Figure 3a , when tumor cells were exposed to 5-FU, the infection efficiency was dramatically higher than that of unexposed cells especially at 10 and 25 MOI analyzed by flow cytometry. Besides, no significant difference of infection efficiency increase was observed between 0.5 lg/mL and 1 lg/mL treated corresponding groups. Therefore, we selected 0.5 lg/ mL for the subsequent experiments. To exclude a direct toxic effect of 5-FU on tumor cells, cell apoptosis was detected. No significant apoptosis in 5-FU treatment alone group was observed. Moreover, adenovirus infection at as high as 50 MOI in the presence of 5-FU did not induce >5% apoptosis similar to that of untreated cells (Fig. 3b) . Then, HepG2 cells were washed after 5-FU treatment, infected by AdCD3scfv at 10, 25 or 50 MOI, and incubated with PBMCs at an E:T ratio of 10:1 subsequently. AdCD3scfv infected alone group displayed 22.42 6 3.89%, 39.43 6 5.18% or 61.87 6 5.39% lysis at 10, 25 or 50 MOI, respectively. In contrast, pretreatment of HepG2 with 5-FU substantially increased PBMCs mediated cytotoxicity of target cells. The corresponding lysis rate reached 36.11 6 2.98%, 59.79 6 7.03%, 79.02 6 4.94%, respectively (Fig. 3c) . Similar results were obtained in IL-2, TNF-a and IFN-g secretion assay (Fig. 3d-f) . Overall, these data indicate that 5-FU sensitizes adenovirus infection and leads to improved cytotoxic effect of PBMCs.
Propagation of adenovirus in E1A modified HUMSC
To confirm the possibility that E1A modified HUMSCs could transform into adenovirus packaging cells, we used AdTrack and LentiR.E1A to co-transfect HUMSCs (MSC.E1A.AdTrack), then quantified the number of hexon gene (late adenoviral gene) in the intracellular and supernatant at indicated time points by the QX200 Droplet Digital PCR. As shown in Figure 4a , the adenoviral replication in intracellular was initiated after 36 hr, sharply increased after 48 hr and declined after 72 hr. Meanwhile, there was almost no virus DNA detected in supernatant at 36 hr, virus DNA emergented apparently delayed to 48 hr, and increased gradually. It still remained a relative high level after 120 hr (Fig.  4a) . The total amount of adenoviral DNA production by MSC.E1A.AdTrack within 72 hr could reach about 6 3 10 6 . In contrast, the control group of MSC.LentiR.AdTrack (AdTrack and LentiR co-transfect HUMSCs) was not detected the adenoviral DNA (Fig. 4b) . Moreover, the intact adenovirus particles were definitely observed in MSC.E1A.AdTrack at 48 hr by electron microscopy (Fig. 4c) . Besides, the supernatant was collected and co-cultured with HepG2 for 2 days in the presence of 5-FU or not. Under the fluorescence microscope, HepG2 cells were infected by new generated adenoviruses successfully in both MSC.E1A.AdTrack and MSC.E1A.AdTrack 1 5-FU group (Fig.  4d) . As detected by flow cytometry, the infection efficiency of adenovirus was improved significantly when combined with 5-FU (Fig. 4e) .
Tumor cells were modified by anti-CD3scfv depended on virus-loaded HUMSC delivery system in established subcutaneous tumor model Transwell assay was conducted to test the migration capacity of the dual-viruses loaded HUMSCs. Since the MSC.E1A.AdTrack would be lysed to release the new packaged adenoviral particles, we set the time point at 36 hr after LentiR.E1A infection to perform this detection according to the adenovirus production time curve (Fig. 4a) . HUMSCs can be attracted by HepG2 cells and no remarkable differences were discovered between the dual viruses-transfected and non-transfected HUMSCs within the 36 hr (Fig. 5a) . Then, we established subcutaneous HepG2 xenografts model and injected these dual viruses-transfected HUMSCs intravenously into each mouse. Immunofluorescence staining demonstrated that at Day 1 after injection, cells only expressing GFP distributed in tumor tissues of all groups. We speculated they were the virus-loaded HUMSCs homing to the tumor. At Day 4, some cells expressing GFP (green) and anti-CD3scfv (red) were observed in group MSC.E1A.AdCD3scfv, because of the re-infection of the adenovirus released from those homed HUMSCs, and this phenomenon maintained until Day 6. Correspondingly, in group MSC.E1A.AdTrack, there were also certain GFP expressions examined at Day 4 and Day 6. However, in E1A deficient group MSC.LentiR.AdCD3scfv, only some GFP-labeled HUMSCs could be detected at Day 1, and was gradually reduced along with the tumor growth (Fig. 5b) .
Anti-CD3scfv transduction system suppressed the growth of established subcutaneous HepG2 xenografts combined with 5-FU To evaluate the antitumor function of anti-CD3scfv introducing system, we established subcutaneous HepG2 xenografts, and then different kinds of virus-load MSCs were injected intravenously followed by PBMCs infusion, respectively. Compared with the control groups, MSC.E1A.AdCD3scfv 1 PBMC group exhibited 48.9% tumor regression after 20 days treatment. Since 5-FU could induce excessive adenoviral infection, we combined with 5-FU additionally to improve the utilization of adenovirus produced in vivo, especially at the low MOI. 5-FU alone group showed a slight inhibition of tumor growth. In contrast, MSC.E1A.AdCD3scfv 1 PBMC 1 5-FU group displayed 66.7% tumor suppression, which was obviously enhanced and showed a synergistic therapeutic effect (Fig. 6b) . Besides, tumor volume also showed similar results among different groups (Fig. 6a) . During the whole treatment period, there were no significant differences in the body weight among all groups (Fig. 6c) .
Discussion
In this study, we successfully modified HCC cells by a constructed membrane-bound anti-CD3scfv gene within the tumor site depending on the virus-loaded HUMSC transgene system. Subsequently, surface expressing anti-CD3scfv mobilized lymphocytes and lysed HCC cells bypassing the expression of antigens or MHC restriction.
Tumor cells with defective antigen expression or presentation are refractive to CTL killing because the low levels of MHC-peptide is inadequate for recognition by CTL. Expression of anti-CD3scfv on tumor cells may be useful for the treatment of poorly immunogenic tumors because activation of T cells by anti-CD3scfv is not MHC-antigen restricted. Besides, that activated lymphocytes are also cytotoxic to wildtype tumor cells except the genetically modified tumor cells. 23, 24 The potency of bystander killing may allow effective tumor regression after transfection of only a subpopulation of the cells. Stable expression of anti-human CD3scfv on cell surface to modify and treat human tumors has not been tested. In the present study, we constructed an adenoviral vector composed by anti-human CD3scfv sequence with a transmembrane domain to transduct human HCC cells and investigated the anti-CD3scfv function in a membrane-bound form. To enhance the anti-tumor specificity and reduce the potential risk to normal cells, we designed the expression of anti-CD3scfv was driven by human AFP promoter. First, we examined its surface expression of the anti-CD3scfv by immunofluorescence and flow cytometry analysis. The specific transcriptional activity of AFP promoter was confirmed as anti-CD3scfv protein was only expressed in two AFP 1 HCC cell lines. To confirm, the surface anti-CD3scfv were active, we detected that lymphocytes could bind to the AdCD3scfv transfected HepG2 cells within 3 hr. Moreover, typical cell interaction, including binding and then lysis in 15 hr, was examined by confocal microscopic video imaging. The function of surface anti-CD3scfv was comprehensively tested from different aspects, including cytotoxicity assay by LDH release, expression of activation markers on lymphocytes by flow cytometry and cytokines levels by ELISA. All results confirmed that this membrane-bound anti-CD3scfv on HCC cells could initiated strong cytotoxicity of PBMCs. Besides, owing to the specificity of AFP promoter, only HepG2 and Huh-7 were lysed among AdCD3scfv transfected cell lines.
It is crucial to select a suitable introducing system for anti-CD3scfv to modify tumor cells and subsequently activate the immune response strictly within the tumor site. We took advantage of an adenovirus-loaded HUMSC.E1A system to deliver, and then produce the AdCD3scfv at the local tumor site. The foundation and mechanism has been described in our previous study: (1) HUMSCs can migrate and accumulate selectively towards the tumor sites; 29, 30, 32, 33 (2) E1A is the most essential element for the replication of adenovirus serotypes 5 (Ad5) and complement E1A protein in host cells will resume the viral replication. 34 In order to exploit the HUMSC.E1A as cellular carriers for AdCD3scfv, it was important to consider the time window when the virusloaded HUMSCs homed to the tumor sites and they were lysed by the produced adenoviruses. On one hand, we infected HUMSCs with adenovirus overnight, and then engineered the HUMSCs by LentiR.E1A. Adenoviral amplification was examined in HUMSCs cells until 36 hr after LentiR.E1A infection and reached the peak at 72 hr; the release of adenoviral particle into supernatant is later. This result is consistent with our previous findings. 30 On the other hand, researchers had traced the MSCs and investigated the kinetic distribution of systemically administered MSCs. In vivo experiments confirmed the preferential localization of MSCs in the tumor periphery 24 hr after tail vein injection, and this localization increased in a time dependent manner within 72 hr. 35 Yan C 32 demonstrated by luciferase bioluminescence in vivo that MSCs migrated to the tumor site at 24 hr after injection. Moreover, we also examined GFP-labled HUMSCs in the tumor section 1 day after intravenous administration. Therefore, according to the time interval between E1A sparking adenoviral replication and HUMSCs migration, virusesloaded HUMSCs will not be lysed by adenoviral production until most of the HUMSCs have already arrived at the tumor sites. In addition, we should bear in mind that mesenchymal stem cells (MSCs) have been shown to be immunosuppressive in both animal disease models and human clinical trials. 36, 37 In this report, viruses-loaded HUMSCs could be cleared ultimately within tumor nodule due to the adenovirus production, which avoided the potential immunosurpression.
Activation of lymphocytes was determined by the density of anti-CD3scfv on the tumor cell surface. To make maximum use of the new generated AdCD3scfv within tumor site, we combined low dose 5-FU with the immunotherapy. It has been demonstrated the expression levels of CAR, amb3 and amb5 essential for adenovirus internalization could be increased in the presence of 5-Fu, which ultimately sensitized adenovirus infection. 38 In this study, we pre-treated HePG2 cells with low dose 5-FU before adenovirus infection in vitro. The infection efficiency was dramatically higher than that of adenoviral treatment alone, particularly at the lower MOI, and led to improved cytotoxic effect of PBMCs. In established subcutaneous HepG2 xenografts, tumor suppression was significantly enhanced in group of MSC.E1A.AdCD3scfv 1 PBMC 1 5-FU and showed a synergistic therapeutic effect.
In conclusion, we investigated a combined cell vehicle and immunotherapy approach against hepatocarcinoma by exploiting anti-CD3scfv to express specifically on the surface of tumor cells in situ. Membrane-bound anti-CD3scfv protein mediated immunotherapy provides a novel therapeutic strategy for tumors bypassing the expression of antigens or MHC restriction. Meanwhile, T cell activation by surface antiCD3scfv is expected to be limited to local tumor-infiltrating lymphocytes, which reduces treatment toxicity.
